GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lantern Pharma Inc.
Lantern, an oncology company using AI for drug discovery, is a bet on its scientific platform. Its price trajectory depends on news from clinical trials confirming the potential of its approach.
Share prices of companies in the market segment - Lungs' cancer
Lantern Pharma is an oncology company that uses artificial intelligence to accelerate the development of targeted drugs. We've classified it under "Lung Cancer" as that's one of its areas of focus. The chart below shows how the market values companies using AI in oncology.
Broad Market Index - GURU.Markets
Lantern Pharma is an oncology company that uses artificial intelligence to accelerate the development of targeted therapies. As a component of the GURU.Markets index, it applies AI to oncology. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
LTRN - Daily change in the company's share price Lantern Pharma Inc.
For Lantern Pharma Inc., which uses AI to develop cancer drugs, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks at the intersection of biotech and artificial intelligence.
Daily change in the price of a set of shares in a market segment - Lungs' cancer
Lantern Pharma Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with LTRN, which uses AI for drug development, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lantern Pharma uses artificial intelligence to develop personalized cancer treatments. The company is located at the intersection of two hot sectors—AI and biotech. This creates high volatility, which contributes to overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lantern Pharma Inc.
Lantern Pharma Inc.'s year-over-year performance is a story of AI in oncology. Its 12-month market cap growth reflects progress in clinical trials of its drugs, which are matched to patients using its RADR® platform. Its valuation is a bet that its approach can improve the efficiency of cancer drug development.
Annual dynamics of market capitalization of the market segment - Lungs' cancer
Lantern Pharma Inc. uses an artificial intelligence platform to accelerate the development of targeted cancer drugs. Its technological approach is aimed at increasing R&D efficiency. The chart shows how the market views its innovative but high-risk model compared to the traditional, slower approach of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lantern, which uses AI to develop cancer drugs, is a hybrid of biotech and IT. Its stock price is a speculative bet that its platform will revolutionize pharmaceuticals. The chart isn't tied to economics, but rather reflects investors' faith in one of the most ambitious ideas at the intersection of two industries.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lantern Pharma Inc.
Lantern Pharma uses AI to develop oncology drugs. Its monthly performance reflects progress in its clinical programs identified using its platform. Trial data and partnership news are key drivers.
Monthly dynamics of market capitalization of the market segment - Lungs' cancer
Lantern Pharma is using AI to accelerate drug development for lung cancer. This approach puts it at the forefront of modern oncology. The chart below shows how investors generally viewed the biotech sector using AI to discover new treatments, and the level of faith in this technological revolution.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lantern Pharma uses AI to develop personalized cancer drugs. Like other AI biotechs, its stock price is driven by two factors: progress in clinical trials and general investor interest in the use of artificial intelligence in medicine. It's a combination of science and technology trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lantern Pharma Inc.
Lantern Pharma uses AI for personalized oncology. The company's weekly stock price is volatile, driven by news of progress in clinical trials of its drugs and partnerships with major pharmaceutical companies. The market is keenly aware of any confirmation of the effectiveness of its AI platform.
Weekly dynamics of market capitalization of the market segment - Lungs' cancer
Lantern Pharma uses AI for personalized oncology. The company's weekly stock price is volatile, driven by news of progress in clinical trials of its drugs and partnerships with major pharmaceutical companies. The market is keenly aware of any confirmation of the effectiveness of its AI platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Lantern, a biotech company, live in a world of their own. Their performance is driven by news about clinical trials. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
LTRN - Market capitalization of the company Lantern Pharma Inc.
Lantern Pharma's market capitalization chart tells the story of how artificial intelligence is being used to rescue and repurpose "forgotten" oncology drugs. Its dynamics reflect investors' belief that AI can find new applications for drugs that have failed in the past. It's a visual representation of how the market is evaluating this innovative R&D approach.
LTRN - Share of the company's market capitalization Lantern Pharma Inc. within the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate oncology drug development. Its share of its segment's market capitalization reflects investors' faith in its innovative platform. The chart below shows how the market views its ability to discover new drug applications and personalize cancer treatment.
Market capitalization of the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to develop personalized oncology drugs. The chart below shows the total market capitalization of the lung cancer treatment sector. It illustrates how AI can accelerate the search for patients most likely to benefit from a specific drug, increasing the chances of success.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows how AI is helping in the fight against cancer. Lantern Pharma uses artificial intelligence to analyze data and select patients most likely to benefit from its drugs. Its approach is a bet that a "smart" approach to clinical trials will make them faster and cheaper.
Book value capitalization of the company, segment and market as a whole
LTRN - Book value capitalization of the company Lantern Pharma Inc.
Lantern Pharma's capital comes from its RADR® artificial intelligence platform for developing personalized oncology drugs and its financial reserves. This represents a unique combination of digital and scientific capital. The chart shows how the company uses this capital to "rescue" and repurpose drugs using AI, accelerating their time to market.
LTRN - Share of the company's book capitalization Lantern Pharma Inc. within the market segment - Lungs' cancer
Lantern Pharma uses AI to develop cancer drugs. Its approach allows it to save on physical infrastructure while focusing on data analysis. The chart shows a minimal share of physical assets, as its "laboratory" is largely its AI platform.
Market segment balance sheet capitalization - Lungs' cancer
As the BCap_Seg chart shows, AI-powered biopharmaceuticals are "lighter" than traditional ones. Lantern Pharma is a prime example. It has invested in developing an AI platform for oncology drug discovery, reducing the need for large physical labs in the early stages.
Book value of all companies included in the broad market index - GURU.Markets
Lantern Pharma's book value is not derived from its laboratories, but from its powerful RADR® artificial intelligence platform and capital. It reflects the financial and IT foundation for data analysis, which enables the discovery of new drug targets, accelerating the development of tangible cancer treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lantern Pharma Inc.
Lantern Pharma uses AI to develop oncology drugs. Its model is similar to BioXcel. Its book value is low, and its market capitalization is a valuation of its AI platform. The MvsBCap chart will demonstrate investor confidence that artificial intelligence can truly speed up and reduce the cost of developing new cancer drugs.
Market to book capitalization ratio in a market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to develop personalized oncology drugs. Its value lies in its RADR® platform. The chart shows how the market values its technological approach to drug discovery over its laboratory assets.
Market to book capitalization ratio for the market as a whole
Lantern Pharma uses AI to accelerate cancer drug development. Its approach helps identify patients most likely to benefit from a drug. The market values this innovative platform more than the drugs themselves. The chart shows how highly valued technologies that make drug development smarter and faster are.
Debts of the company, segment and market as a whole
LTRN - Company debts Lantern Pharma Inc.
Lantern Pharma is using its AI platform to accelerate oncology drug development. The capital raised is being used to validate AI predictions in laboratory and clinical trials. This chart shows how the innovative company is funding its unique approach to making cancer drug development faster and more cost-effective.
Market segment debts - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate oncology drug development. This approach can reduce risks and costs. A company's debt policy may reflect its confidence in its AI platform. This chart shows how Lantern is funding its innovative approach to creating personalized cancer drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lantern Pharma Inc.
Lantern Pharma uses AI to develop personalized cancer drugs. This chart reflects its financial strategy, which is based on raising funds for high-tech research. High debt in this sector is an investment in the future, but it also creates pressure for rapid commercialization and successful clinical trials.
Market segment debt to market segment book capitalization - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate the development of personalized oncology drugs. This chart reflects debt trends in the biotech sector. It allows us to assess how the company is funding its technology platform and clinical programs in its quest to make cancer treatment more precise and effective.
Debt to book value of all companies in the market
Lantern Pharma uses artificial intelligence to accelerate the development of cancer drugs, particularly lung cancer. The overall debt burden shown in this chart provides a backdrop for the entire biotech industry. The availability of capital for funding high-tech R&D projects is directly dependent on macroeconomic stability and investor sentiment.
P/E of the company, segment and market as a whole
P/E - Lantern Pharma Inc.
This chart for Lantern Pharma, which uses AI to develop oncology drugs, shows the market valuation of its technology platform. The high values reflect investors' belief that artificial intelligence will help discover new lung cancer treatments more effectively than traditional approaches.
P/E of the market segment - Lungs' cancer
This chart shows the average P/E for the biotech sector where Lantern Pharma uses AI. The industry's high valuation reflects a belief in new approaches. This metric helps understand the premium the market places on Lantern's technology platform compared to other oncology companies.
P/E of the market as a whole
Lantern Pharma uses artificial intelligence to accelerate the development of personalized cancer drugs. The company's platform analyzes data to select patients who are most likely to benefit from a drug. This chart shows biotech sentiment. It helps understand whether the market believes Lantern's AI approach can truly improve the chances of success in clinical trials and how this is reflected in its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lantern Pharma Inc.
Lantern Pharma uses artificial intelligence to accelerate the development of personalized cancer treatments, particularly for lung cancer. The company's valuation is based on the potential of its AI platform. This chart shows how confident analysts are in the company's ability to discover new therapeutic solutions faster and more cost-effectively than traditional methods.
%20P%2FE%20Lantern%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lantern-Pharma-Inc.&v=1772644683403 "Chart of the company's future (projected) P/E Lantern Pharma Inc.")
Future (projected) P/E of the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate oncology drug development, matching drugs to patients most likely to respond. This chart shows analysts' estimates of its future revenue, reflecting their confidence in its platform and the potential of personalized medicine in cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Lungs-cancer&v=1772644683683 "Future (projected) P/E graph of the market segment - Lungs' cancer")
Future (projected) P/E of the market as a whole
Lantern Pharma uses AI to accelerate cancer drug development. By combining biotechnology and artificial intelligence, the company attracts growth-focused investors. This market valuation chart shows how much the market is willing to pay for such advanced business models. During periods of optimism, companies like Lantern command higher valuations.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772644683753 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lantern Pharma Inc.
Lantern Pharma Inc. uses artificial intelligence to accelerate cancer drug development. The company's goal is profitability, and its current finances are driven by investments in R&D. This chart shows how the company uses its platform to analyze data and identify patients most likely to respond to therapy, aiming to make oncology more personalized.
Profit of companies in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence and machine learning to accelerate the development of personalized oncology drugs. Its RADR® platform helps identify patients for clinical trials. This graph illustrates how technology is changing pharmaceuticals, enabling the development of more targeted and effective drugs, increasing the chances of success and profitability.
Overall market profit
Lantern Pharma uses AI to accelerate oncology drug development. Funding is a key need. This chart, reflecting the state of the markets, shows how willing investors are to invest in high-tech platforms that promise to transform the pharmaceutical industry but are associated with high risks.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lantern Pharma Inc.
Lantern Pharma uses artificial intelligence to accelerate the development of personalized oncology drugs. The company's platform helps identify patients who are most likely to benefit from a drug. This chart reflects analysts' expectations for the effectiveness of this approach and the commercial potential of the company's drug portfolio.
%20profit%20of%20the%20company%20Lantern%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lantern-Pharma-Inc.&v=1772644684002 "Graph of future (projected) profit of the company Lantern Pharma Inc.")
Future (predicted) profit of companies in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence and machine learning to accelerate the development of personalized oncology drugs. The company's platform analyzes data to select patients who are most likely to benefit from a drug. This chart shows profitability forecasts for the biotech sector, highlighting the potential of AI to transform cancer drug development.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Lungs-cancer&v=1772644684073 "Graph of future (predicted) profits of companies in a market segment - Lungs' cancer")
Future (predicted) profit of the market as a whole
Lantern Pharma uses artificial intelligence to develop personalized oncology drugs. The company requires ongoing investment for its research. The overall corporate profit forecast, presented in the chart, forms the investment backdrop and influences the market's willingness to finance advanced, yet capital-intensive, medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772644684099 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lantern Pharma Inc.
Lantern Pharma uses AI to develop oncology drugs. This chart reflects how highly the market values its technology platform. Its high price-to-sales ratio suggests investors believe its AI approach can accelerate and reduce the cost of developing new cancer drugs.
P/S market segment - Lungs' cancer
Lantern Pharma Inc. uses artificial intelligence to accelerate the development of personalized cancer drugs. This chart shows the average revenue estimate in the biotech sector. It helps understand the premium investors are willing to pay for Lantern's innovative platform and its ability to improve the efficiency of cancer drug discovery.
P/S of the market as a whole
Lantern Pharma uses artificial intelligence to accelerate the development of personalized oncology drugs. Their RADR® platform analyzes data to select patients who are most likely to benefit from a drug. This chart provides a general revenue metric that can be used to assess how investors value the use of AI in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lantern Pharma Inc.
Lantern Pharma uses artificial intelligence to accelerate the development of personalized cancer treatments. This chart reflects investor expectations for its AI platform. The valuation is based on future revenues that could arise from partnerships and the successful launch of drugs developed using its unique approach.
%20P%2FS%20Lantern%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lantern-Pharma-Inc.&v=1772644684191 "The graph of the company's future (projected) P/S Lantern Pharma Inc.")
Future (projected) P/S of the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate the development of personalized cancer treatments. Its platform analyzes data to tailor the drug to the individual patient. This chart shows how the market views its technological approach to oncology compared to traditional biopharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Lungs-cancer&v=1772644684195 "Future (projected) P/S market segment graph - Lungs' cancer")
Future (projected) P/S of the market as a whole
Lantern Pharma uses artificial intelligence to accelerate the development of cancer drugs, particularly lung cancer. This chart, reflecting investor willingness to invest in innovative pharmaceutical approaches, is important to Lantern. Market optimism facilitates funding for companies like Lantern that strive to make drug discovery faster and cheaper.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772644684217 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lantern Pharma Inc.
Lantern Pharma uses artificial intelligence to accelerate the development of personalized oncology drugs. This chart shows financial flows, which may include payments from partners and grants. It does not represent commercial revenue, but rather funding for an innovative approach aimed at matching the right drug with the right patient.
Sales of companies in the market segment - Lungs' cancer
Lantern Pharma Inc. uses artificial intelligence and machine learning to accelerate oncology drug development. The company's business can be segmented by various drug development programs for specific cancer types, identified by its RADR® platform. This chart depicts the financial flows associated with one of these AI-focused projects.
Overall market sales
Lantern Pharma Inc. uses artificial intelligence to accelerate cancer drug development. The AI platform analyzes data and predicts which patients will benefit from a particular drug. This approach has the potential to significantly improve the efficiency of oncology R&D. The company's growth reflects the trend toward personalized medicine and the use of big data.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lantern Pharma Inc.
Lantern Pharma is a biopharmaceutical company using artificial intelligence to develop personalized cancer treatments. Its future sales forecast is based on the expected success of its clinical programs, which target patients with specific genetic biomarkers, thereby increasing the effectiveness of therapy.
%20sales%20of%20the%20company%20Lantern%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lantern-Pharma-Inc.&v=1772644684278 "Schedule of future (projected) sales of the company Lantern Pharma Inc.")
Future (projected) sales of companies in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate the development of personalized cancer treatments. This chart reflects expectations for the lung cancer treatment sector. It helps assess the potential of AI platforms for drug discovery and the progress analysts predict in personalized oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Lungs-cancer&v=1772644684319 "Schedule of future (projected) sales of companies in the market segment - Lungs' cancer")
Future (projected) sales of the market as a whole
Lantern Pharma uses AI to develop personalized cancer treatments. Its success depends on investing in innovative medicine. This chart of overall sales forecasts reflects the overall economic sentiment, which influences investor willingness to invest in long-term, high-tech biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772644684362 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lantern Pharma Inc.
Lantern Pharma Inc. uses artificial intelligence to accelerate cancer drug development. The company focuses on personalized oncology. This chart reflects its financial performance at the R&D stage, where investments in its AI platform and clinical trials are the foundation for developing future targeted therapies and achieving profitability.
Market segment marginality - Lungs' cancer
Lantern Pharma uses AI and machine learning to accelerate oncology drug development. Their goal is to improve R&D efficiency. This chart evaluates whether their technology platform results in higher operating margins compared to biotech companies using traditional drug discovery methods.
Market marginality as a whole
Lantern Pharma Inc. uses artificial intelligence to accelerate cancer drug development. The company's platform analyzes data to select patients and predict drug efficacy. This graph illustrates the profitability of traditional pharma, but for LTRN, an innovative, data-driven approach to R&D could fundamentally change the economics of drug development.
Employees in the company, segment and market as a whole
Number of employees in the company Lantern Pharma Inc.
Lantern Pharma uses artificial intelligence to accelerate oncology drug development. This graph shows its team, where data analytics specialists play a key role. The team's compact size reflects its business model, which relies on computing power to improve R&D efficiency.
Share of the company's employees Lantern Pharma Inc. within the market segment - Lungs' cancer
Lantern Pharma uses AI to accelerate the development of oncology drugs, particularly for lung cancer. Its platform requires a team of bioinformatics and oncology specialists. This graph reflects its innovative approach and the scale of its human investment in personalized medicine.
Number of employees in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate oncology drug development. Specializing in lung cancer, the company operates in one of the most active segments. This chart, showing oncology employment, illustrates the scale of the industry. Lantern's approach is aimed at improving R&D efficiency in this vast and competitive field.
Number of employees in the market as a whole
Lantern Pharma uses AI to develop personalized oncology drugs. Its business model is based on innovation. This chart shows overall employment, but Lantern's primary focus is proving the effectiveness of its platform, which attracts partners and investment, allowing it to recruit top AI and oncology specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. uses artificial intelligence to develop personalized oncology drugs. The high market cap per employee in this chart reflects the combination of AI and biotech. The market values a scalable platform that enables a small team to efficiently develop new drugs.
%20of%20the%20company%20Lantern%20Pharma%20Inc.%20(LTRN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lantern-Pharma-Inc.-LTRN&v=1772644684731 "Chart of market capitalization per employee (in thousands of dollars) of the company Lantern Pharma Inc. (LTRN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate the development of cancer drugs, particularly lung cancer. For a company at the intersection of AI and biotech, this metric reflects how highly the market values their innovative platform. It demonstrates investors' confidence in the team's ability to efficiently and quickly develop new drugs.
%20by%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Lungs-cancer&v=1772644684746 "Market capitalization per employee (in thousands of dollars) by market segment - Lungs' cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Lantern Pharma Inc. uses artificial intelligence and genomic data to accelerate the development of personalized cancer drugs. Their goal is to "rescue" failed treatments by matching them with the right patients. The chart demonstrates the high ratings for their innovative model, which combines AI and oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772644684773 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lantern Pharma Inc. (LTRN)
Lantern Pharma is a clinical-stage biopharmaceutical company using its AI platform (RADR®) to develop precision oncology drugs, including for lung cancer. This graph is likely negative. It doesn't represent profit, but rather R&D intensity—how much capital the company invests in each employee (scientist, data scientist) to advance its AI developments toward commercialization.
%20Chart%20Lantern%20Pharma%20Inc.%20(LTRN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lantern-Pharma-Inc.-LTRN&v=1772644684800 "Company Profit Per Employee (in thousands of dollars) Chart Lantern Pharma Inc. (LTRN)")
Profit per employee (in thousands of dollars) in the market segment - Lungs' cancer
Lantern Pharma uses artificial intelligence to accelerate the development of oncology drugs, particularly for lung cancer. Their approach is designed to achieve results with a smaller team. This chart demonstrates how their AI platform improves employee productivity in value generation compared to traditional pharmaceutical R&D methods.
%20in%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Lungs-cancer&v=1772644684820 "Chart of profit per employee (in thousands of dollars) in the market segment - Lungs' cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Lantern Pharma uses AI to develop targeted oncology drugs. It's an R&D platform that aims to reduce the cost and speed up drug discovery. This metric, likely negative, reflects the "cost" of its team of scientists and programmers. Investors use it to assess how efficiently their AI platform spends capital on the path to commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772644684886 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lantern Pharma Inc. (LTRN)
Lantern Pharma uses artificial intelligence to accelerate oncology drug development. This chart illustrates how technology can boost R&D productivity. While revenue may be low in the early stages, the success of its platform will lead to dramatic growth through partnerships and licensing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lantern-Pharma-Inc.-LTRN&v=1772644684897 "Sales chart per company employee Lantern Pharma Inc. (LTRN)")
Sales per employee in the market segment - Lungs' cancer
Lantern Pharma uses AI and machine learning to accelerate oncology drug development. They rescue and repurpose failed drugs. This chart compares Lantern's revenue per employee to the industry average. It demonstrates how effective their AI platform is at identifying high-value candidates compared to traditional R&D.
Sales per employee for the market as a whole
Lantern Pharma uses AI and machine learning to accelerate cancer drug development, particularly for lung cancer. It's a technology-enhanced R&D business. While in the clinical stage, the company has no sales revenue. This graph would show $0. Revenue growth will only begin after successful clinical trials, partnerships, or drug approval.
Short shares by company, segment and market as a whole
Shares shorted by company Lantern Pharma Inc. (LTRN)
Lantern Pharma (LTRN) uses AI to develop personalized oncology drugs. They're trying to "revive" failed drugs by finding the right patient groups for them. It's an interesting, but speculative, model. This chart shows the number of investors who don't believe the company's AI platform can succeed where "old" pharma failed.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lantern-Pharma-Inc.-LTRN&v=1772644684932 "Short Shares Chart for the Company Lantern Pharma Inc. (LTRN)")
Shares shorted by market segment - Lungs' cancer
Lantern Pharma uses AI and machine learning to accelerate cancer drug development. They analyze data to determine which patients their targeted drugs will help the most. This chart shows the odds against the "AI in pharma" sector, reflecting investor doubts that AI can truly reduce the time and cost of drug development.
Shares shorted by the overall market
Lantern Pharma (LTRN) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse that require refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lantern Pharma Inc. (LTRN)
Lantern Pharma uses AI to develop personalized cancer treatments. This is a bet that their AI platform will be more effective than traditional methods. This oscillator measures investor confidence in this technology, showing "overheated" (above 70) on partnership news or "oversold" (below 30) pending data.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lantern-Pharma-Inc.-LTRN&v=1772644684957 "RSI 14 indicator chart for the company's stock Lantern Pharma Inc. (LTRN)")
RSI 14 Market Segment - Lungs' cancer
Lantern Pharma is an oncology company using an AI platform (RADR) to analyze data and accelerate the development of targeted therapies for cancer, including lung cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by expectations of breakthroughs in AI medicine.
RSI 14 for the overall market
For Lantern Pharma, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LTRN (Lantern Pharma Inc.)
Lantern Pharma uses AI (RADR platform) to accelerate the development of targeted oncology drugs. This chart shows the average analyst forecast. Their targets are based on the potential of the company's AI platform to discover new drugs and the progress of its candidates in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LTRN-Lantern-Pharma-Inc.&v=1772644684978 "A chart showing analyst consensus forecasts for the expected stock price. LTRN (Lantern Pharma Inc.)")
The difference between the consensus estimate and the actual stock price LTRN (Lantern Pharma Inc.)
Lantern Pharma is an oncology company that uses its AI platform (RADR) to analyze data and "rescue" drug candidates. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe their AI approach can truly speed up and reduce the cost of cancer drug development.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LTRN-Lantern-Pharma-Inc.&v=1772644684979 "A chart showing the difference between the consensus forecast and the actual stock price. LTRN (Lantern Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Lungs' cancer
Lantern Pharma is a biotech company using an AI platform (RADR) to rescue and repurpose old, failed oncology drugs. This chart shows general expectations for the lung cancer sector, reflecting whether experts believe in AI's ability to find new uses for old drugs.
Analysts' consensus forecast for the overall market share price
Lantern Pharma is a biotech company that uses AI and machine learning to accelerate cancer drug development by rescuing and repurposing failed drugs. This chart shows the overall "risk appetite" in the market. For Lantern, which operates at the intersection of AI and biotech, overall optimism (risk appetite) is critical to funding its high-tech research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lantern Pharma Inc.
Lantern is an AI oncologist. They don't just test drugs; they use their AI platform (RADR®) to predict which lung cancer patients (and others) will benefit from their targeted therapies. This graph is a summary indicator of their AI model. It reflects their R&D progress and the market's confidence in the success and cost-effectiveness of their precision approach to oncology.
AKIMA Market Segment Index - Lungs' cancer
Lantern Pharma (LTRN) uses its RADR AI platform to modernize drug development in oncology. They identify patient biomarkers to help them select targeted therapies, including for lung cancer. This chart shows the average index value for the segment, allowing investors to assess whether Lantern's data-driven approach creates a strategic advantage over the average.
The AKIM Index for the overall market
Lantern Pharma is a biotech company using AI (the RADR platform) to rescue and develop oncology drugs abandoned by others. This chart, which reflects the market average, is a backdrop. It helps assess how this data-driven R&D risk reduction model compares to overall macroeconomic trends.
